삼천당제약 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 윤대인, was filed 10 Jul 2023.
삼천당제약: what insiders have been doing
삼천당제약, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). Between 2 November 2025 and 2 November 2026, 1 insider published 2 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
With 2 filings in twelve months, the company is quieter than the median of 7 filings across the 2,655 companies we follow on the same exchange. Looking back to 2021, when coverage begins, insiders filed 1 purchase and no sales.
No insider has bought 삼천당제약 shares on the open market in the past twelve months.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
About 삼천당제약
Samchundang Pharmaceutical is a South Korean pharmaceutical company focused on the development and manufacturing of medications. It is listed on the XKRX market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
